Dietary, cofactor and emergency management of metabolic disease

Overview & Definition

Imagine a child whose body cannot fully clear one specific molecule — an amino acid, a fatty acid, or a sugar — because a single enzyme is missing or sluggish. The treatment is not a drug that "cures" the missing enzyme; it is a way of living that keeps the blocked pathway from overflowing. That way of living has three habits and one emergency plan: eat around the block by restricting substrate body cannot handle, take the vitamin that can wake up a sluggish enzyme, and never let a fever or a skipped meal tip the body into breaking down its own protein — and when it does, reverse that catabolism fast.^[3]

This is the territory of dietary, cofactor and emergency management of inherited metabolic disease (IMD). The dietary pillar restricts the offending substrate (protein in the aminoacidopathies and urea cycle disorders, long-chain fat in the fatty-acid oxidation defects) while supplying enough safe energy and an otherwise complete diet so the child grows.^[7] The cofactor pillar gives supraphysiological doses of a vitamin that restores residual enzyme activity — biotin in biotinidase deficiency, cobalamin in some methylmalonic acidaemias, pyridoxine and folate in homocystinuria, sapropterin in tetrahydrobiopterin-responsive phenylketonuria.^[5] The emergency pillar is the sick-day regimen, a pre-written plan that floods the child with glucose to switch the body from breakdown to storage the moment a fever, fast, or surgical stress begins.^[2]

References12ShowHide

1. [1]Summar ML, Mew NA Inborn Errors of Metabolism with Hyperammonemia: Urea Cycle Defects and Related Disorders Pediatr Clin North Am, 2018.PMID 29502911
2. [2]Servais A, Abi-Wardé MT, Arnoux JB, et al. Management of acute metabolic decompensation in maple syrup urine disease: guidance based on international clinical practice Orphanet J Rare Dis, 2026.PMID 42251408
3. [3]Van Gosen L Organic acidemias: a methylmalonic and propionic focus J Pediatr Nurs, 2008.PMID 18492552
4. [4]Pillai NR, Stroup BM, Poliner A, et al Liver transplantation in propionic and methylmalonic acidemia: A single center study with literature review Mol Genet Metab, 2019.PMID 31757659
5. [5]Wolf B The neurology of biotinidase deficiency Mol Genet Metab, 2011.PMID 21696988
6. [6]Smith WE, Berry SA, Bloom K, et al. Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG) Genet Med, 2025.PMID 39630157
7. [7]Van Calcar SC, Sowa AT, Rohr F, et al Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): An evidence- and consensus-based approach Mol Genet Metab, 2020.PMID 33093005
8. [8]Boy N, Mühlhausen C, Maier EM, et al. Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision J Inherit Metab Dis, 2023.PMID 36221165
9. [9]Morris AA, Kožich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency J Inherit Metab Dis, 2017.PMID 27778219
10. [10]Williams RA, Bell DA, Hooper AJ, et al. Sepiapterin for the treatment of phenylketonuria Expert Opin Pharmacother, 2025.PMID 40272408
11. [11]Chinen Y, Nakamura S, Tamashiro K, et al. Isovaleric acidemia: Therapeutic response to supplementation with glycine, L-carnitine, or both in combination and a 10-year follow-up case study Mol Genet Metab Rep, 2017.PMID 30547004
12. [12]Yu Y, Zhang Q, Yang Y, et al Different mutations in the MMUT gene are associated with the effect of vitamin B12 in a cohort of 266 Chinese patients with mut-type methylmalonic acidemia: A retrospective study Mol Genet Genomic Med, 2021.PMID 34668645